Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA

Fig. 6

Exosomal lncRNA PART1 promotes gefitinib resistance by activating Bcl-2 signaling pathway. a Histogram shows the fold changes for the activities of different signaling pathways, as indicated by reporter activity. b Western blot analysis showed that knockdown of SNHG14 reversed the effect of exosomal treatment. c TUNEL assay showed that exosome treatment inhibited cell apoptosis levels, but this effect was abrogated by simultaneous treatment of Bcl-2 inhibitor venetoclax. **P < 0.01 compared to Exosome group. d Treatment with venetoclax abrogated the PART1-induced gefitinib resistance. ***P < 0.01 compared to negative control group

Back to article page